CTRI/2013/06/003734进行中（未招募）3 期
ow dose chemotherapy (Metronomic Therapy) versus Best Supportive Care in Progressive and/or Refractory Pediatric Malignancies: a double blind placebo controlled randomized study
il0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Refractory/Progressive non hematopoietic extracranial solid tumors following treatment with atleast 2 lines of chemotherapy.
- •2.Good performance status (at least ambulatory patient)
- •3.Age: 5-18 years
- •4.Recovered from all acute toxic effects of earlier therapy
- •5.Absolute neutrophil count > 1X 109/L
- •6.Absolute platelet count > 75 x 109/L
- •7.Normal renal functions
- •8.Serum bilirubin <1.5 times the upper limit of normal, and the serum aspartate aminotransferase and alanine aminotransferase < 5 times the upper limit of normal.
排除标准
- •1.Uncontrolled concurrent illness or active infection
- •2.Positive serology for human immunodeficiency.
- •3.Unable to swallow oral medication
- •4.Pregnant and breast-feeding
研究者
相似试验
已完成
不适用
Reduced intensity chemotherapy given with and without imatinib mesylate in patients >/= 60 years considered unfit for standard chemotherapy with previously untreated acute myeloid leukemia (AML) and refractory anemia with excess of blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T): a randomized phase II studyAcute myeloid leukemia (AML)CancerLeukemiaISRCTN70542454Dutch Haemato-oncology Association (Stichting Hemato-Oncologie Volwassenen Nederland) (HOVON)60
进行中（未招募）
1 期
Shortened vs standard chemotherapy combined with immunotherapy for the initial treatment of patients with Follicular LymphomaHigh tumor burden Follicular LymphomaMedDRA version: 24.0Level: LLTClassification code 10080213Term: In situ follicular lymphomaSystem Organ Class: 100000004864EUCTR2020-003277-22-ITFONDAZIONE ITALIANA LINFOMI ONLUS602
进行中（未招募）
1 期
Metronomic chemotherapy in elderly non-fit patients with aggressive B-Cell lymphomas. Phase II studyB-Cell lymphomasMedDRA version: 21.0Level: LLTClassification code 10012855Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation)System Organ Class: 100000004864EUCTR2016-003703-62-ITFONDAZIONE ITALIANA LINFOMI ONLUS60
进行中（未招募）
不适用
Treatment With Chemotherapy and Antiretroviral Therapy in Patients With Diffuse Large B Cell Lymphoma and Infection With the Human Immunodeficiency Virus (HIV)Diffuse Large B Cell Lymphoma and HIV InfectionEUCTR2006-003750-23-ESFundación PETHEMA
未知
1 期
Clinical evaluation of NK211 and CDDP for cervical cancer.Advanced and/or recurrent cervical cancer.JPRN-jRCT2080221794ippon Kayaku Co., Ltd.